GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/HCC/HCC Without Cirrhosis - Child-Pugh and ALBI Scores Still Predict Survival: JHEP Reports | October 2026
1

HCC Without Cirrhosis - Child-Pugh and ALBI Scores Still Predict Survival: JHEP Reports | October 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2026

What Did the Study Find?

This international study evaluated whether Child-Turcotte-Pugh (CTP) classification and albumin-bilirubin (ALBI) grade retain prognostic value in patients with hepatocellular carcinoma (HCC) without underlying cirrhosis.

  • The analysis included 2,457 patients with unresectable HCC, comprising 443 without cirrhosis and 2,014 with cirrhosis.
  • Two independent cohorts were evaluated: a European HCC cohort and an international cohort receiving atezolizumab/bevacizumab or durvalumab/tremelimumab.
  • In noncirrhotic HCC, CTP classification independently predicted overall survival, even after adjustment for BCLC stage and other prognostic factors.
  • Worse CTP classification was associated with approximately threefold higher mortality risk in both cohorts (adjusted HR 3.04 and 3.24).
  • ALBI grade also independently predicted survival, with prognostic performance comparable to CTP classification.
  • Importantly, the predictive performance of both scores was comparable between cirrhotic and noncirrhotic HCC populations.
  • These findings suggest that liver functional reserve remains prognostically relevant even when established cirrhosis is absent.

Why Does It Matter?

HCC prognosis is traditionally determined by tumour burden, liver function and performance status. However, clinicians may underestimate the importance of liver functional assessment when HCC develops without cirrhosis, particularly in patients with MASLD/MASH or chronic hepatitis B.

This study demonstrates that the absence of cirrhosis does not eliminate the prognostic importance of hepatic functional impairment.

GastroAGI Takeaway

In HCC, assess liver function even when the patient does not have cirrhosis.

Both Child-Pugh classification and ALBI grade provide meaningful survival stratification in noncirrhotic HCC, supporting their incorporation alongside BCLC staging and performance status.

ALBI is particularly attractive because it uses only albumin and bilirubin, providing a simple, objective and reproducible assessment.

Related Q&A

02

HCC Treatment Trials: Expert Consensus Redefines How Systemic Therapy Should Be Studied With Surgery and Locoregional Treatment: JHEP | October 2026

What Does the Consensus Recommend? An international multidisciplinary panel developed 18 consensus statements—nine addressing neoadjuvant/perioperative systemic therapy and nine addressing systemic therapy combined with locoregional treatment. Prioritize high-risk...

03

STRIDE Shows Feasibility in High-Risk HCC Patients Excluded From Pivotal Trials: Journal of Hepatology | October 2026

What Did the Study Find? SIERRA prospectively evaluated first-line STRIDE—one dose of tremelimumab 300 mg plus durvalumab 1,500 mg, followed by durvalumab every four weeks—in 111 patients with...

04

ICI-Based Downstaging Before Liver Transplant in HCC: JAMA Oncology | October 2026

What Did the Study Find? This study examined whether immune checkpoint inhibitor (ICI)-based multimodal therapy before liver transplantation can improve outcomes in selected patients with HCC initially beyond...

05

BEACON-HCC: Moving HCC Treatment Beyond Stage-Based Allocation: Hepatology | August 2026

Introduction: HCC treatment has traditionally been closely linked to staging systems such as BCLC. However, modern multidisciplinary care increasingly includes TARE, external-beam radiotherapy, systemic therapy, and combined approaches...

06

Perioperative Immunotherapy Is Redefining Curative-Intent HCC Treatment: JHEP Reports | September 2026

Introduction: Resection and liver transplantation remain the main curative-intent treatments for hepatocellular carcinoma (HCC), but recurrence after surgery is common and many patients present outside conventional surgical or...

07

What Comes After Atezolizumab–Bevacizumab in HCC: JHEP Reports | September 2026

Introduction: Immunotherapy-based combinations have transformed first-line treatment of unresectable HCC, but the optimal strategy after progression remains uncertain because no phase III trial has yet defined a standard...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer